1
|
Qi D, Tian X, Wang Y, Zheng G, Zhang X. BMP2 variants in the risk of ankylosing spondylitis. J Cell Biochem 2020; 121:3935-3940. [PMID: 31713925 DOI: 10.1002/jcb.29563] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/19/2019] [Accepted: 10/10/2019] [Indexed: 01/24/2023]
Abstract
The purpose of the study was to explore the genetic effects of bone morphogenetic protein (BMP2) polymorphisms on the susceptibility to ankylosing spondylitis (AS) in Chinese Han population. The case-control study included 120 AS cases and 110 healthy controls. Hardy-Weinberg equilibrium test was performed in control group. BMP2 rs235768 and rs3178250 polymorphisms were analyzed by polymerase chain reaction and direct sequencing. Additionally, the χ2 test was used to estimate association strength between BMP2 genetic polymorphisms and AS susceptibility, and the results were assessed via odds ratio (OR) with the corresponding 95% confidence interval (95%CI). Results adjustment was performed using logistic regression analysis. AA, AT, TT genotype and A, T allele frequencies of BMP2 rs235768 polymorphism presented no significant differences between case and control groups (P > .05 for all). TC genotype of rs3178250 polymorphism showed significantly higher in case group than that in control group (P = .048). After adjusting, TC genotype was a risk factor for AS (OR = 2.095; 95%CI = 1.086-4.038; P = .027). BMP2 rs3178250 polymorphism may increase individual susceptibility to AS in Chinese Han population.
Collapse
Affiliation(s)
- Dengbin Qi
- Department of Orthopedics, General Hospital of PLA, Beijing, China
| | - Xiaodong Tian
- Department of Orthopedics, The Second Hospital of Jinzhou, Jinzhou, China
| | - Yan Wang
- Department of Orthopedics, General Hospital of PLA, Beijing, China
| | - Guoquan Zheng
- Department of Orthopedics, General Hospital of PLA, Beijing, China
| | - Xuesong Zhang
- Department of Orthopedics, General Hospital of PLA, Beijing, China
| |
Collapse
|
2
|
Luttropp K, Debowska M, Lukaszuk T, Bobrowski L, Carrero JJ, Qureshi AR, Stenvinkel P, Lindholm B, Waniewski J, Nordfors L. Genotypic and phenotypic predictors of inflammation in patients with chronic kidney disease. Nephrol Dial Transplant 2016; 31:2033-2040. [PMID: 27190335 DOI: 10.1093/ndt/gfw066] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/15/2016] [Accepted: 03/07/2016] [Indexed: 01/07/2023] Open
Abstract
BACKGROUND In complex diseases such as chronic kidney disease (CKD), the risk of clinical complications is determined by interactions between phenotypic and genotypic factors. However, clinical epidemiological studies rarely attempt to analyse the combined effect of large numbers of phenotype and genotype features. We have recently shown that the relaxed linear separability (RLS) model of feature selection can address such complex issues. Here, it is applied to identify risk factors for inflammation in CKD. METHODS The RLS model was applied in 225 CKD stage 5 patients sampled in conjunction with dialysis initiation. Fifty-seven anthropometric or biochemical measurements and 79 genetic polymorphisms were entered into the model. The model was asked to identify phenotypes and genotypes that, when combined, could separate inflamed from non-inflamed patients. Inflammation was defined as a high-sensitivity C-reactive protein concentration above the median (5 mg/L). RESULTS Among the 60 genotypic and phenotypic features predicting inflammation, 31 were genetic. Among the 10 strongest predictors of inflammation, 8 were single nucleotide polymorphisms located in the NAMPT, CIITA, BMP2 and PIK3CB genes, whereas fibrinogen and bone mineral density were the only phenotypic biomarkers. CONCLUSION These results indicate a larger involvement of hereditary factors in inflammation than might have been expected and suggest that inclusion of genotype features in risk assessment studies is critical. The RLS model demonstrates that inflammation in CKD is determined by an extensive panel of factors and may prove to be a suitable tool that could enable a much-needed multifactorial approach as opposed to the commonly utilized single-factor analysis.
Collapse
Affiliation(s)
- Karin Luttropp
- Department of Molecular Medicine and Surgery, Neurogenetics Division, Center for Molecular Medicine, Karolinska Institutet, Stockholm, Sweden
| | - Malgorzata Debowska
- Institute of Biocybernetics and Biomedical Engineering, Polish Academy of Sciences, Warsaw, Poland
| | | | - Leon Bobrowski
- Institute of Biocybernetics and Biomedical Engineering, Polish Academy of Sciences, Warsaw, Poland.,Bialystok University of Technology, Bialystok, Poland
| | - Juan Jesus Carrero
- Department of Molecular Medicine and Surgery, Neurogenetics Division, Center for Molecular Medicine, Karolinska Institutet, Stockholm, Sweden.,Divisions of Renal Medicine and Baxter Novum, Department of Clinical Science, Intervention and Technology, Karolinska Institutet, Stockholm, Sweden
| | - Abdul Rashid Qureshi
- Divisions of Renal Medicine and Baxter Novum, Department of Clinical Science, Intervention and Technology, Karolinska Institutet, Stockholm, Sweden
| | - Peter Stenvinkel
- Divisions of Renal Medicine and Baxter Novum, Department of Clinical Science, Intervention and Technology, Karolinska Institutet, Stockholm, Sweden
| | - Bengt Lindholm
- Divisions of Renal Medicine and Baxter Novum, Department of Clinical Science, Intervention and Technology, Karolinska Institutet, Stockholm, Sweden
| | - Jacek Waniewski
- Institute of Biocybernetics and Biomedical Engineering, Polish Academy of Sciences, Warsaw, Poland
| | - Louise Nordfors
- Department of Molecular Medicine and Surgery, Neurogenetics Division, Center for Molecular Medicine, Karolinska Institutet, Stockholm, Sweden.,Divisions of Renal Medicine and Baxter Novum, Department of Clinical Science, Intervention and Technology, Karolinska Institutet, Stockholm, Sweden
| |
Collapse
|
3
|
Rusek AM, Abba M, Eljaszewicz A, Moniuszko M, Niklinski J, Allgayer H. MicroRNA modulators of epigenetic regulation, the tumor microenvironment and the immune system in lung cancer. Mol Cancer 2015; 14:34. [PMID: 25743773 PMCID: PMC4333888 DOI: 10.1186/s12943-015-0302-8] [Citation(s) in RCA: 53] [Impact Index Per Article: 5.9] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/26/2014] [Accepted: 01/21/2015] [Indexed: 12/11/2022] Open
Abstract
Cancer is an exceedingly complex disease that is orchestrated and driven by a combination of multiple aberrantly regulated processes. The nature and depth of involvement of individual events vary between cancer types, and in lung cancer, the deregulation of the epigenetic machinery, the tumor microenvironment and the immune system appear to be especially relevant. The contribution of microRNAs to carcinogenesis and cancer progression is well established with many reports and investigations describing the involvement of microRNAs in lung cancer, however most of these studies have concentrated on single microRNA-target relations and have not adequately addressed the complexity of their interactions. In this review, we focus, in part, on the role of microRNAs in the epigenetic regulation of lung cancer where they act as active molecules modulating enzymes that take part in methylation-mediated silencing and chromatin remodeling. Additionally, we highlight their contribution in controlling and modulating the tumor microenvironment and finally, we describe their role in the critical alteration of essential molecules that influence the immune system in lung cancer development and progression.
Collapse
Affiliation(s)
- Anna Maria Rusek
- Department of Clinical Molecular Biology, Medical University of Bialystok, Waszyngtona 13, Białystok, 15-269, Poland.
- Department of Experimental Surgery, Medical Faculty Mannheim, Heidelberg University, Theodor Kutzer Ufer 1-3, 68135, Mannheim, Germany.
- Molecular Oncology of Solid Tumors, DKFZ (German Cancer Research Centre), Im Neuenheimer Feld 280, 69120, Heidelberg, Germany.
| | - Mohammed Abba
- Department of Experimental Surgery, Medical Faculty Mannheim, Heidelberg University, Theodor Kutzer Ufer 1-3, 68135, Mannheim, Germany.
- Molecular Oncology of Solid Tumors, DKFZ (German Cancer Research Centre), Im Neuenheimer Feld 280, 69120, Heidelberg, Germany.
| | - Andrzej Eljaszewicz
- Department of Regenerative Medicine and Immune Regulation, Medical University of Bialystok, Bialystok, Waszyngtona 13, Białystok, 15-269, Poland.
| | - Marcin Moniuszko
- Department of Regenerative Medicine and Immune Regulation, Medical University of Bialystok, Bialystok, Waszyngtona 13, Białystok, 15-269, Poland.
| | - Jacek Niklinski
- Department of Clinical Molecular Biology, Medical University of Bialystok, Waszyngtona 13, Białystok, 15-269, Poland.
| | - Heike Allgayer
- Department of Experimental Surgery, Medical Faculty Mannheim, Heidelberg University, Theodor Kutzer Ufer 1-3, 68135, Mannheim, Germany.
- Molecular Oncology of Solid Tumors, DKFZ (German Cancer Research Centre), Im Neuenheimer Feld 280, 69120, Heidelberg, Germany.
| |
Collapse
|
4
|
Breitfeld J, Martens S, Klammt J, Schlicke M, Pfäffle R, Krause K, Weidle K, Schleinitz D, Stumvoll M, Führer D, Kovacs P, Tönjes A. Genetic analyses of bone morphogenetic protein 2, 4 and 7 in congenital combined pituitary hormone deficiency. BMC Endocr Disord 2013; 13:56. [PMID: 24289245 PMCID: PMC4175098 DOI: 10.1186/1472-6823-13-56] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/10/2013] [Accepted: 10/28/2013] [Indexed: 12/15/2022] Open
Abstract
BACKGROUND The complex process of development of the pituitary gland is regulated by a number of signalling molecules and transcription factors. Mutations in these factors have been identified in rare cases of congenital hypopituitarism but for most subjects with combined pituitary hormone deficiency (CPHD) genetic causes are unknown. Bone morphogenetic proteins (BMPs) affect induction and growth of the pituitary primordium and thus represent plausible candidates for mutational screening of patients with CPHD. METHODS We sequenced BMP2, 4 and 7 in 19 subjects with CPHD. For validation purposes, novel genetic variants were genotyped in 1046 healthy subjects. Additionally, potential functional relevance for most promising variants has been assessed by phylogenetic analyses and prediction of effects on protein structure. RESULTS Sequencing revealed two novel variants and confirmed 30 previously known polymorphisms and mutations in BMP2, 4 and 7. Although phylogenetic analyses indicated that these variants map within strongly conserved gene regions, there was no direct support for their impact on protein structure when applying predictive bioinformatics tools. CONCLUSIONS A mutation in the BMP4 coding region resulting in an amino acid exchange (p.Arg300Pro) appeared most interesting among the identified variants. Further functional analyses are required to ultimately map the relevance of these novel variants in CPHD.
Collapse
Affiliation(s)
- Jana Breitfeld
- Department of Medicine, University of Leipzig, Liebigstrasse 20, Leipzig 04103, Germany
- IFB Adiposity Diseases, University of Leipzig, Philipp-Rosenthal-Str. 27, Leipzig 04103, Germany
| | - Susanne Martens
- Department of Medicine, University of Leipzig, Liebigstrasse 20, Leipzig 04103, Germany
- IFB Adiposity Diseases, University of Leipzig, Philipp-Rosenthal-Str. 27, Leipzig 04103, Germany
| | - Jürgen Klammt
- Hospital for Children & Adolescents, University of Leipzig, Liebigstrasse 22, Leipzig 04103, Germany
| | - Marina Schlicke
- Hospital for Children & Adolescents, University of Leipzig, Liebigstrasse 22, Leipzig 04103, Germany
| | - Roland Pfäffle
- Hospital for Children & Adolescents, University of Leipzig, Liebigstrasse 22, Leipzig 04103, Germany
| | - Kerstin Krause
- Department of Medicine, University of Leipzig, Liebigstrasse 20, Leipzig 04103, Germany
| | - Kerstin Weidle
- Department of Medicine, University of Leipzig, Liebigstrasse 20, Leipzig 04103, Germany
| | - Dorit Schleinitz
- Department of Medicine, University of Leipzig, Liebigstrasse 20, Leipzig 04103, Germany
| | - Michael Stumvoll
- Department of Medicine, University of Leipzig, Liebigstrasse 20, Leipzig 04103, Germany
| | - Dagmar Führer
- Department of Endocrinology, University of Essen, Hufelandstraße 55, Essen 45147, Germany
| | - Peter Kovacs
- Department of Medicine, University of Leipzig, Liebigstrasse 20, Leipzig 04103, Germany
- IFB Adiposity Diseases, University of Leipzig, Philipp-Rosenthal-Str. 27, Leipzig 04103, Germany
| | - Anke Tönjes
- Department of Medicine, University of Leipzig, Liebigstrasse 20, Leipzig 04103, Germany
- IFB Adiposity Diseases, University of Leipzig, Philipp-Rosenthal-Str. 27, Leipzig 04103, Germany
| |
Collapse
|
5
|
Li L, Li H. Role of microRNA-mediated MMP regulation in the treatment and diagnosis of malignant tumors. Cancer Biol Ther 2013; 14:796-805. [PMID: 23917402 DOI: 10.4161/cbt.25936] [Citation(s) in RCA: 46] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022] Open
Abstract
Matrix metalloproteinases (MMPs) play important roles in tumor cell proliferation and apoptosis and contribute to tumor growth, angiogenesis, migration, and invasion primarily via extracellular matrix (ECM) degradation and/or the activation of pre-pro-growth factors. Recently, there has been considerable interest in the posttranscriptional regulation of MMPs via microRNAs (miRs). In this review, we highlight the complicated interactive network comprised of different MMPs and their regulating microRNAs, as well as the ways in which these interactions influence cancer development, including tumor angiogenesis, growth, invasion, and metastasis. Based on the conclusive roles that microRNAs play in the regulation of MMPs during cancer progression, we discuss the potential use of microRNA-mediated MMP regulation in the diagnosis and treatment of tumors from the clinical perspective. In particular, microRNA-mediated MMP regulation may lead to the development of promising new MMP inhibitors that target MMPs more selectively, and this approach may also target multiple molecules in a network, leading to the efficient regulation of distinct biological processes relevant to malignant tumors. A thorough understanding of the mechanisms underlying microRNA-mediated MMP regulation during tumor progression will help to provide new insights into the diagnosis and treatment of malignant tumors.
Collapse
Affiliation(s)
- Liqin Li
- Huzhou Key Laboratory of Molecular Medicine; Huzhou Central Hospital; Huzhou, China
| | - Heng Li
- The First Affiliated Hospital of Huzhou Teachers College; The First People's Hospital of Huzhou; Huzhou, China
| |
Collapse
|